ABVC Historical Balance Sheet

ABVC Stock

USD 0.80 0.01 1.48%

Trend analysis of ABVC Biopharma balance sheet accounts such as Short Long Term Debt Total of 1.9 M, Total Current Liabilities of 7.2 M or Total Stockholder Equity of 10.1 M provides information on ABVC Biopharma's total assets, liabilities, and equity, which is the actual value of ABVC Biopharma to its prevalent stockholders. By breaking down trends over time using ABVC Biopharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ABVC Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ABVC Biopharma is a good buy for the upcoming year.

ABVC Biopharma Inventory

1.58 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.

About ABVC Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of ABVC Biopharma at a specified time, usually calculated after every quarter, six months, or one year. ABVC Biopharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ABVC Biopharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ABVC currently owns. An asset can also be divided into two categories, current and non-current.

ABVC Biopharma Balance Sheet Chart

At present, ABVC Biopharma's Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 10.1 M, whereas Short and Long Term Debt Total is forecasted to decline to about 1.9 M.

Total Assets Short Long Term Debt Total Total Current Liabilities Common Stock Shares Outstanding

Add Fundamental

Total Assets

Total assets refers to the total amount of ABVC Biopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ABVC Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on ABVC Biopharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of ABVC Biopharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most accounts from ABVC Biopharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into ABVC Biopharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.At present, ABVC Biopharma's Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 10.1 M, whereas Short and Long Term Debt Total is forecasted to decline to about 1.9 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	3.1M	2.3M	2.6M	1.9M
Total Assets	9.9M	14.5M	16.7M	17.5M

Short Long Term Debt Total Total Assets

ABVC Biopharma balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Other Current Liab	Current Deferred Revenue	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock	Net Receivables	Other Current Assets	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Common Stock Total Equity	Property Plant And Equipment Gross
Total Assets		0.59	0.78	0.93	0.31	-0.74	-0.03	0.16	0.6	0.84	0.81	0.6	0.56	0.71	0.74	-0.35	0.38	0.4	-0.48	0.79	0.78	0.84	0.89	0.11	-0.23	0.81
Short Long Term Debt Total	0.59		0.59	0.39	0.44	-0.32	-0.2	0.57	-0.14	0.3	0.77	0.65	0.82	0.35	0.1	-0.24	0.58	0.59	-0.27	0.69	0.63	0.23	0.37	0.04	-0.3	0.19
Total Current Liabilities	0.78	0.59		0.52	0.64	-0.68	-0.2	0.08	0.49	0.69	0.95	0.3	0.72	0.91	0.6	-0.27	0.08	0.1	-0.25	0.56	0.56	0.67	0.87	0.32	0.11	0.65
Total Stockholder Equity	0.93	0.39	0.52		0.09	-0.68	0.08	0.06	0.65	0.81	0.54	0.56	0.34	0.48	0.75	-0.3	0.37	0.38	-0.52	0.72	0.73	0.83	0.77	0.0	-0.38	0.81
Net Debt	0.31	0.44	0.64	0.09		-0.37	-0.12	0.08	0.29	0.36	0.58	-0.3	0.62	0.46	0.39	0.03	-0.45	-0.44	-0.29	0.05	0.03	0.38	0.51	0.14	-0.12	0.38
Retained Earnings	-0.74	-0.32	-0.68	-0.68	-0.37		0.2	-0.17	-0.76	-0.96	-0.62	-0.31	-0.43	-0.59	-0.73	-0.14	-0.06	-0.08	0.35	-0.56	-0.64	-0.75	-0.74	-0.37	0.28	-0.75
Common Stock Shares Outstanding	-0.03	-0.2	-0.2	0.08	-0.12	0.2		-0.2	0.07	-0.12	-0.19	-0.06	-0.23	-0.11	-0.04	-0.25	-0.05	-0.05	-0.25	-0.06	-0.03	0.02	-0.02	0.04	-0.16	0.03
Non Current Liabilities Total	0.16	0.57	0.08	0.06	0.08	-0.17	-0.2		-0.35	0.12	0.33	0.43	0.24	-0.09	-0.08	0.42	0.53	0.52	-0.14	0.2	0.21	-0.03	-0.05	0.01	-0.17	-0.05
Inventory	0.6	-0.14	0.49	0.65	0.29	-0.76	0.07	-0.35		0.82	0.32	-0.06	0.03	0.57	0.8	-0.07	-0.34	-0.32	-0.25	0.31	0.37	0.79	0.75	0.26	-0.12	0.8
Other Stockholder Equity	0.84	0.3	0.69	0.81	0.36	-0.96	-0.12	0.12	0.82		0.64	0.31	0.38	0.63	0.85	0.03	0.07	0.09	-0.41	0.56	0.64	0.88	0.84	0.31	-0.3	0.87
Total Liab	0.81	0.77	0.95	0.54	0.58	-0.62	-0.19	0.33	0.32	0.64		0.48	0.73	0.85	0.51	-0.31	0.31	0.32	-0.26	0.65	0.63	0.62	0.81	0.29	0.04	0.59
Total Current Assets	0.6	0.65	0.3	0.56	-0.3	-0.31	-0.06	0.43	-0.06	0.31	0.48		0.41	0.21	0.0	-0.3	0.94	0.95	-0.24	0.87	0.85	0.16	0.22	0.01	-0.22	0.12
Short Term Debt	0.56	0.82	0.72	0.34	0.62	-0.43	-0.23	0.24	0.03	0.38	0.73	0.41		0.4	0.18	-0.1	0.27	0.27	-0.44	0.6	0.56	0.26	0.45	0.01	-0.25	0.23
Other Current Liab	0.71	0.35	0.91	0.48	0.46	-0.59	-0.11	-0.09	0.57	0.63	0.85	0.21	0.4		0.64	-0.43	0.01	0.02	-0.05	0.44	0.43	0.7	0.88	0.41	0.33	0.68
Current Deferred Revenue	0.74	0.1	0.6	0.75	0.39	-0.73	-0.04	-0.08	0.8	0.85	0.51	0.0	0.18	0.64		-0.09	-0.18	-0.17	-0.28	0.25	0.3	0.98	0.88	0.3	-0.18	0.99
Accounts Payable	-0.35	-0.24	-0.27	-0.3	0.03	-0.14	-0.25	0.42	-0.07	0.03	-0.31	-0.3	-0.1	-0.43	-0.09		-0.25	-0.25	-0.02	-0.37	-0.28	-0.21	-0.33	-0.05	-0.08	-0.19
Cash	0.38	0.58	0.08	0.37	-0.45	-0.06	-0.05	0.53	-0.34	0.07	0.31	0.94	0.27	0.01	-0.18	-0.25		1.0	-0.13	0.66	0.64	-0.04	-0.01	-0.07	-0.16	-0.08
Cash And Short Term Investments	0.4	0.59	0.1	0.38	-0.44	-0.08	-0.05	0.52	-0.32	0.09	0.32	0.95	0.27	0.02	-0.17	-0.25	1.0		-0.14	0.68	0.66	-0.02	0.01	-0.06	-0.17	-0.06
Common Stock	-0.48	-0.27	-0.25	-0.52	-0.29	0.35	-0.25	-0.14	-0.25	-0.41	-0.26	-0.24	-0.44	-0.05	-0.28	-0.02	-0.13	-0.14		-0.31	-0.32	-0.31	-0.32	0.42	0.3	-0.31
Net Receivables	0.79	0.69	0.56	0.72	0.05	-0.56	-0.06	0.2	0.31	0.56	0.65	0.87	0.6	0.44	0.25	-0.37	0.66	0.68	-0.31		0.98	0.41	0.51	0.14	-0.33	0.37
Other Current Assets	0.78	0.63	0.56	0.73	0.03	-0.64	-0.03	0.21	0.37	0.64	0.63	0.85	0.56	0.43	0.3	-0.28	0.64	0.66	-0.32	0.98		0.45	0.51	0.25	-0.4	0.41
Property Plant And Equipment Net	0.84	0.23	0.67	0.83	0.38	-0.75	0.02	-0.03	0.79	0.88	0.62	0.16	0.26	0.7	0.98	-0.21	-0.04	-0.02	-0.31	0.41	0.45		0.93	0.33	-0.21	1.0
Non Current Assets Total	0.89	0.37	0.87	0.77	0.51	-0.74	-0.02	-0.05	0.75	0.84	0.81	0.22	0.45	0.88	0.88	-0.33	-0.01	0.01	-0.32	0.51	0.51	0.93		0.28	-0.01	0.92
Non Currrent Assets Other	0.11	0.04	0.32	0.0	0.14	-0.37	0.04	0.01	0.26	0.31	0.29	0.01	0.01	0.41	0.3	-0.05	-0.07	-0.06	0.42	0.14	0.25	0.33	0.28		-0.12	0.32
Common Stock Total Equity	-0.23	-0.3	0.11	-0.38	-0.12	0.28	-0.16	-0.17	-0.12	-0.3	0.04	-0.22	-0.25	0.33	-0.18	-0.08	-0.16	-0.17	0.3	-0.33	-0.4	-0.21	-0.01	-0.12		-0.21
Property Plant And Equipment Gross	0.81	0.19	0.65	0.81	0.38	-0.75	0.03	-0.05	0.8	0.87	0.59	0.12	0.23	0.68	0.99	-0.19	-0.08	-0.06	-0.31	0.37	0.41	1.0	0.92	0.32	-0.21

Click cells to compare fundamentals

ABVC Biopharma Account Relationship Matchups

ABVC Biopharma balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	11.6M	13.7M	9.9M	14.5M	16.7M	17.5M
Short Long Term Debt Total	6.5M	3.1M	3.1M	2.3M	2.6M	1.9M
Total Current Liabilities	4.8M	3.7M	5.8M	5.9M	6.8M	7.2M
Total Stockholder Equity	3.4M	8.8M	3.1M	8.4M	9.6M	10.1M
Net Debt	2.2M	(2.7M)	3.0M	2.2M	2.6M	2.7M
Retained Earnings	(25.6M)	(38.5M)	(54.9M)	(65.4M)	(58.9M)	(55.9M)
Common Stock Shares Outstanding	2.0M	2.5M	3.2M	4.3M	3.9M	4.1M
Liabilities And Stockholders Equity	11.6M	13.7M	9.9M	14.5M	16.7M	17.5M
Non Current Liabilities Total	4.1M	1.1M	420.2K	429.1K	493.5K	915.9K
Inventory	(477.0K)	(839.7K)	26.0K	1.3M	1.5M	1.6M
Other Stockholder Equity	28.5M	46.8M	57.5M	73.3M	84.3M	88.5M
Total Liab	8.9M	4.8M	6.2M	6.4M	7.3M	7.7M
Total Current Assets	6.2M	9.6M	3.0M	1.7M	1.9M	1.4M
Short Term Debt	2.4M	2.0M	2.3M	1.9M	2.2M	1.3M
Other Current Liab	2.4M	1.7M	3.3M	3.9M	4.4M	4.7M
Cash	4.3M	5.8M	85.3K	60.2K	69.2K	65.7K
Cash And Short Term Investments	4.3M	5.9M	161.1K	139.5K	160.4K	152.4K
Common Stock	24.4K	28.9K	32.9K	7.9K	9.1K	8.7K
Net Receivables	999.4K	1.7M	1.4M	759.6K	873.5K	625.0K
Other Current Assets	900.4K	1.9M	1.5M	757.7K	871.3K	914.9K
Property Plant And Equipment Net	2.3M	2.0M	1.7M	8.8M	10.1M	10.6M
Non Current Assets Total	5.4M	4.1M	6.9M	12.8M	14.8M	15.5M
Non Currrent Assets Other	164.8K	160.5K	1.3M	1.5M	1.8M	1.8M
Property Plant And Equipment Gross	2.3M	2.0M	1.7M	12.1M	13.9M	14.6M
Accumulated Other Comprehensive Income	564.9K	539.7K	517.1K	516.4K	593.8K	396.8K
Net Tangible Assets	(5.7M)	(151.0K)	3.4M	8.8M	10.2M	10.7M
Other Assets	1.4M	1.6M	2.0M	1.1M	1.3M	1.4M
Short Long Term Debt	2.1M	1.8M	1.9M	1.5M	1.7M	2.0M
Other Liab	27.5K	2.9K	19.3K	10.6K	12.2K	11.0K
Short Term Investments	1.2M	108.1K	75.8K	79.3K	71.4K	67.8K
Long Term Investments	1.2M	932.8K	842.1K	2.5M	2.9M	1.8M
Property Plant Equipment	510.1K	1.0M	2.3M	2.0M	2.3M	2.4M
Net Invested Capital	8.1M	10.7M	5.0M	9.9M	11.3M	11.9M
Net Working Capital	1.3M	5.9M	(2.8M)	(4.3M)	(4.9M)	(4.7M)
Capital Stock	24.4K	28.9K	32.9K	7.9K	7.1K	6.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:

How To Invest In ABVC

Details

Is ABVC Stock a good investment?

Details

What is ABVC Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.81)

Revenue Per Share

0.051

Quarterly Revenue Growth

23.507

Return On Assets

(0.25)

Return On Equity

(1.02)

The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ABVC Historical Balance Sheet

ABVC Biopharma Inventory

1.58 Million

About ABVC Balance Sheet Analysis

ABVC Biopharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Common Stock Shares Outstanding

ABVC Biopharma balance sheet Correlations

ABVC Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ABVC Biopharma balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.99	Current Deferred Revenue
Property Plant And Equipment Net	+ 0.98	Current Deferred Revenue
Other Current Assets	+ 0.98	Net Receivables
Total Liab	+ 0.95	Total Current Liabilities

Other Stockholder Equity	- 0.96	Retained Earnings
Inventory	- 0.76	Retained Earnings
Property Plant And Equipment Gross	- 0.75	Retained Earnings
Property Plant And Equipment Net	- 0.75	Retained Earnings
Non Current Assets Total	- 0.74	Retained Earnings
Retained Earnings	- 0.74	Total Assets